This observational study is led by renowned Dr. Since the start of the COVID-19 pandemic, Asili marshaled its resources to conduct clinical studies of therapeutic remedies under the guidance of doctors and researchers at Tanzania’s premier research facility, The National Institute for Medical Research (NIMR). The daily case load in East Africa has kept steady with moderate and severe patients and we hope Artemisinin can be an affordable frontline treatment during the current COVID-19 pandemic here and elsewhere in resource limited countries.”Īsili is a group of scientists dedicated to improving health care equity in Tanzania. Our researchers in Tanzania are eager to start this trial, commencing as early as next month, to learn more about Artemisinin and generate new information for the management and control of COVID-19 in Tanzania. If clinically proven effective, Artemisinin can provide relief to overwhelmed medical infrastructure and families affected by the pandemic in resource limited countries.Įxecutive Director, Jennifer Woltz and Director of Research, Justin Omolo at Asili said “We are thrilled to partner with Mateon in the effort to study Artemisinin as a potential therapy for the COVID-19 pandemic. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and Safety Index = 140. ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. AGOURA HILLS, Calif., J(GLOBE NEWSWIRE) - Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research Alliance (Asili) of Tanzania.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |